2/6
12:44 pm
acad
ACADIA Pharmaceuticals (NASDAQ:ACAD) had its price target raised by analysts at Oppenheimer Holdings, Inc. from $21.00 to $23.00. They now have a "market perform" rating on the stock.
Low
Report
ACADIA Pharmaceuticals (NASDAQ:ACAD) had its price target raised by analysts at Oppenheimer Holdings, Inc. from $21.00 to $23.00. They now have a "market perform" rating on the stock.
2/6
08:43 am
acad
ACADIA Pharmaceuticals (NASDAQ:ACAD) had its "market perform" rating reaffirmed by analysts at Oppenheimer Holdings, Inc..
Low
Report
ACADIA Pharmaceuticals (NASDAQ:ACAD) had its "market perform" rating reaffirmed by analysts at Oppenheimer Holdings, Inc..
2/4
04:27 pm
acad
Acadia Pharmaceuticals to Announce Fourth Quarter and Full Year 2025 Financial Results on February 25, 2026 [Yahoo! Finance]
Medium
Report
Acadia Pharmaceuticals to Announce Fourth Quarter and Full Year 2025 Financial Results on February 25, 2026 [Yahoo! Finance]
2/4
04:05 pm
acad
Acadia Pharmaceuticals to Announce Fourth Quarter and Full Year 2025 Financial Results on February 25, 2026
Medium
Report
Acadia Pharmaceuticals to Announce Fourth Quarter and Full Year 2025 Financial Results on February 25, 2026
2/3
01:07 pm
acad
Exploring US High Growth Tech Stocks This February 2026 [Yahoo! Finance]
Low
Report
Exploring US High Growth Tech Stocks This February 2026 [Yahoo! Finance]
2/3
11:33 am
acad
Acadia Pharmaceuticals' Rett Syndrome Medication Less Likely to Receive EU Approval, RBC Says [Yahoo! Finance]
Low
Report
Acadia Pharmaceuticals' Rett Syndrome Medication Less Likely to Receive EU Approval, RBC Says [Yahoo! Finance]
2/3
09:11 am
acad
ACADIA Pharmaceuticals (NASDAQ:ACAD) was given a new $31.00 price target on by analysts at Royal Bank Of Canada.
Medium
Report
ACADIA Pharmaceuticals (NASDAQ:ACAD) was given a new $31.00 price target on by analysts at Royal Bank Of Canada.
2/3
08:44 am
acad
ACADIA Pharmaceuticals (NASDAQ:ACAD) had its "market outperform" rating reaffirmed by analysts at Citizens Jmp. They now have a $34.00 price target on the stock.
Medium
Report
ACADIA Pharmaceuticals (NASDAQ:ACAD) had its "market outperform" rating reaffirmed by analysts at Citizens Jmp. They now have a $34.00 price target on the stock.
2/3
08:03 am
acad
ACADIA Pharmaceuticals (NASDAQ:ACAD) had its "buy" rating reaffirmed by analysts at HC Wainwright. They now have a $37.00 price target on the stock.
Medium
Report
ACADIA Pharmaceuticals (NASDAQ:ACAD) had its "buy" rating reaffirmed by analysts at HC Wainwright. They now have a $37.00 price target on the stock.
2/3
03:38 am
acad
The Bull Case For ACADIA Pharmaceuticals (ACAD) Could Change Following EMA Setback For Trofinetide Approval [Yahoo! Finance]
Low
Report
The Bull Case For ACADIA Pharmaceuticals (ACAD) Could Change Following EMA Setback For Trofinetide Approval [Yahoo! Finance]
2/3
12:00 am
acad
Acadia Faces EMA Setback On Rett Drug As Regulatory Test Looms [Yahoo! Finance]
Low
Report
Acadia Faces EMA Setback On Rett Drug As Regulatory Test Looms [Yahoo! Finance]
2/2
09:43 pm
acad
Is It Too Late To Consider ACADIA Pharmaceuticals (ACAD) After Its Recent Share Price Rebound? [Yahoo! Finance]
Low
Report
Is It Too Late To Consider ACADIA Pharmaceuticals (ACAD) After Its Recent Share Price Rebound? [Yahoo! Finance]
2/2
04:28 pm
acad
Acadia Pharmaceuticals Provides Update on Regulatory Submission for Trofinetide for the Treatment of Rett Syndrome in the European Union [Yahoo! Finance]
Low
Report
Acadia Pharmaceuticals Provides Update on Regulatory Submission for Trofinetide for the Treatment of Rett Syndrome in the European Union [Yahoo! Finance]
2/2
04:05 pm
acad
Acadia Pharmaceuticals Provides Update on Regulatory Submission for Trofinetide for the Treatment of Rett Syndrome in the European Union
Medium
Report
Acadia Pharmaceuticals Provides Update on Regulatory Submission for Trofinetide for the Treatment of Rett Syndrome in the European Union
1/13
02:18 pm
acad
ACADIA Pharmaceuticals Targets $1.7B Sales by 2028, Maps Key Remlifansirin Readouts at JPM Conf [Yahoo! Finance]
Low
Report
ACADIA Pharmaceuticals Targets $1.7B Sales by 2028, Maps Key Remlifansirin Readouts at JPM Conf [Yahoo! Finance]
1/13
09:26 am
acad
Acadia Pharmaceuticals Provides Business and Pipeline Updates at 44th Annual J.P. Morgan Healthcare Conference [Yahoo! Finance]
Low
Report
Acadia Pharmaceuticals Provides Business and Pipeline Updates at 44th Annual J.P. Morgan Healthcare Conference [Yahoo! Finance]
1/13
09:00 am
acad
Acadia Pharmaceuticals Provides Business and Pipeline Updates at 44th Annual J.P. Morgan Healthcare Conference
Low
Report
Acadia Pharmaceuticals Provides Business and Pipeline Updates at 44th Annual J.P. Morgan Healthcare Conference
1/11
01:03 am
acad
ACADIA Pharmaceuticals (NASDAQ:ACAD) was upgraded by analysts at
Wall St
Low
Report
ACADIA Pharmaceuticals (NASDAQ:ACAD) was upgraded by analysts at
Wall St
1/6
10:05 am
acad
ACADIA Pharmaceuticals (NASDAQ:ACAD) was given a new $40.00 price target on by analysts at UBS Group AG. They now have a "buy" rating on the stock.
Low
Report
ACADIA Pharmaceuticals (NASDAQ:ACAD) was given a new $40.00 price target on by analysts at UBS Group AG. They now have a "buy" rating on the stock.
1/6
07:07 am
acad
ACADIA Pharmaceuticals (NASDAQ:ACAD) had its "buy" rating reaffirmed by analysts at Citigroup Inc..
Medium
Report
ACADIA Pharmaceuticals (NASDAQ:ACAD) had its "buy" rating reaffirmed by analysts at Citigroup Inc..
1/5
08:42 am
acad
ACADIA Pharmaceuticals (NASDAQ:ACAD) had its "buy" rating reaffirmed by analysts at Needham & Company LLC.
Low
Report
ACADIA Pharmaceuticals (NASDAQ:ACAD) had its "buy" rating reaffirmed by analysts at Needham & Company LLC.
1/3
01:06 am
acad
ACADIA Pharmaceuticals (NASDAQ:ACAD) was downgraded by analysts at
Wall
Low
Report
ACADIA Pharmaceuticals (NASDAQ:ACAD) was downgraded by analysts at
Wall
12/30
04:09 pm
acad
ACADIA Pharmaceuticals (NASDAQ:ACAD) had its "hold (c+)" rating reaffirmed by analysts at
Weiss Ratings.
Low
Report
ACADIA Pharmaceuticals (NASDAQ:ACAD) had its "hold (c+)" rating reaffirmed by analysts at
Weiss Ratings.
12/23
04:09 pm
acad
ACADIA Pharmaceuticals (NASDAQ:ACAD) had its "hold (c+)" rating reaffirmed by analysts at
Weiss Ratings.
Low
Report
ACADIA Pharmaceuticals (NASDAQ:ACAD) had its "hold (c+)" rating reaffirmed by analysts at
Weiss Ratings.
12/20
09:41 pm
acad
Assessing ACADIA Pharmaceuticals (ACAD) Valuation After Its Strong 1-Year Share Price Rally [Yahoo! Finance]
Low
Report
Assessing ACADIA Pharmaceuticals (ACAD) Valuation After Its Strong 1-Year Share Price Rally [Yahoo! Finance]